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The acceptance of nucleic acid probes as diagnostic tools for the clinical laboratory has been
hampered by a number of factors, including laborious techniques and limited sensitivity. The
focus ofthis review is on the recent development ofamplification techniques to enhance thesignal
generated by nucleic acid-based detection systems. Three general areas are discussed: (1)
amplification oftarget sequences using the polymerase chain reaction or thetranscript amplifica-
tion system, (2) amplification ofthe probe sequences using Q,B replicase, and (3) amplification of
probe-generated signals with compound or "Christmas tree" probes. The hope of these new
technologies is tosimplify yet improveon thesensitivity ofnucleic acid-based tests toenablethem
to attain a more prominent place in the diagnostic repertoire ofthe clinical laboratory.
INTRODUCTION
The application of the techniques of modern molecular biology to the diagnosis of
human disease has recently made significant advances. Some of the most successful
applications have been in clinical conditions where classical biochemical markers are
either unknown or are inaccessible; under these circumstances, nucleic acid analysis
may be the only means ofproviding diagnostically relevant information [1]. Examples
include restriction fragment length polymorphism (RFLP) analysis in thediagnosis of
Huntington's chorea trait in affected families [2,3], cystic fibrosis heterozygosity in
genetic screening programs [4], and gene rearrangements in lymphomas and leuke-
mias [5]. Other efforts have focused on the diagnosis of infectious agents; the agents
chosen for study have typically been those whose identification and characterization
are hampered by the lack of a suitable system for in vitro cultivation or a paucity of
identifying features [7,9-11].
Despite such advances, however, the acceptance ofnucleic acid probes as diagnostic
tools in the clinical laboratory has been slow to develop. This delay has generally been
ascribed to the difficulties in conveying a basic research tool to the clinical laboratory.
If maximum sensitivity is sought, radiolabeling of such probes with potentially
hazardous radioisotopes such as 32P is a requirement. The relatively short half-life of
32P-labeled probes dictates that the probes be resynthesized on a regular basis, thus
increasing radioisotope exposure and intensifying the need forstringent batch-to-batch
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quality control. Furthermore, while many technical improvements have been made, the
routine use of radiolabeled probes is still tedious and difficult to automate. The most
critical shortcoming, however, is limited sensitivity; this problem is especially apparent
in the diagnosis ofinfectious diseases. The limit ofdetection for even the most sensitive
nucleic acid probes, around 103 to 104 molecules [20], is still insufficient for direct
detection from many clinical samples, in which the number of pathogens varies
tremendously and is often small. For this reason, probes for infectious agents have
remained largely confined to use in culture confirmation and have not yet obviated the
need for primary culture.
The focus of this review is on the recent development of amplification techniques to
enhance the signal generated from nucleic acid-based detection systems. The intent of
all of these techniques is to provide greatly increased levels of sensitivity, thus raising
the possibility that, in certain cases, genetic amplification may replace biological
amplification (i.e., growth in culture) as the initial step in the identification scheme.
While the use of such techniques is by no means limited to the diagnosis of infectious
diseases, it is probably in this area that they offer the greatest promise. In particular,
the clinical diagnostic virology laboratory stands to benefit greatly from these
techniques because of the difficulty and expense associated with viral culture. Indeed,
the first demonstrations of the utility of these approaches have been in the diagnosis of
infection with viral pathogens whose detection prior to the introduction of amplifica-
tion techniques has been difficult or impossible.
AMPLIFICATION METHODS: THE MAINSTAY OF FUTURE
MOLECULAR DIAGNOSTIC TECHNIQUES
In this review, we will describe several means of increasing the sensitivity of nucleic
acid-based tests using amplification techniques. Because the field is broad and the
techniques are varied, we will divide the subject into three general areas: (1)
amplification of target sequences using the polymerase chain reaction (PCR) or the
transcript amplification system (TAS), (2) amplification of probe sequences using the
Q,B replicase system, and (3) amplification of probe-generated signals with compound
or "Christmas tree" probes (Table 1). It should be added that coincident with the
development of these techniques has been the ability to synthesize DNA oligonucleo-
tides of known sequence easily and inexpensively; all of these methods rely heavily on
specific base pairing between oligonucleotides and their target sequences.
Regardless of the detection scheme used, unambiguous identification of an infec-
tious agent depends on the identification of distinguishing nucleic acid sequences.
Several groups have focused their efforts on detection of ribosomal RNA. The high
copy number of this species lends itself well to direct detection from patient samples;
however, the evolutionary pressure to maintain ribosomal RNA structure dictates that
interspecies sequence differences be relatively small. The hybridization conditions
required for adequate sensitivity and specificity must therefore be stringently con-
trolled; this requirement may not be practical in some settings. The ideal nucleic acid
sequence used for detection purposes would be one that is entirely unique to that
organism (or that bears substantial sequence divergence from homologous regions of
related species), yet is present in sufficiently high copy number to allow maximum
sensitivity. Such sequences can be identified by several means, such as differential
screening of genomic clones or subtractive hybridization of complementary DNA
(cDNA) clones [37,38].
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TABLE 1
Amplification Methods
1. Target Amplification
Polymerase chain reaction
Transcript amplification system
2. Probe Amplification
Qft replicase
3. Signal Amplification
Enzyme-linked probes
Compound ("Christmas tree")
probes
Once unique nucleic acid fragments are identified, their nucleotide sequence should
be determined and examined for sequence heterogeneity among a number of clinical
isolates. The reason for this qualification is that while the gross structure and
nucleotide composition of a nucleic acid fragment may be conserved, there may exist
regions of microheterogeneity that will preclude efficient base-pairing of the probes
generated against the target sequence. The efficiency of base pairing becomes more
critical as the probes become shorter, such as in the use ofoligonucleotides as probes or
primers. If the criteria are met for sequence conservation in the target regions of a
variety of clinical isolates, these may be confidently targeted for amplification, using
one or a combination ofthe approaches described below.
TARGET AMPLIFICATION METHODS: PCR AND TAS
The Polymerase Chain Reaction
In 1985, scientists at the Cetus Corporation described an in vitro genetic amplifica-
tion technique known as the polymerase chain reaction (PCR) [15,39-41,46]. This
method uses repeated cycles ofoligonucleotide-directed DNA synthesis to carry out in
vitro replication oftarget nucleic acid sequences (Fig. 1). The oligonucleotides used in
a given reaction are synthesized to be complementary to their annealing sites within
the two different strands (the sense and nonsense strands) of a target sequence, from
150 to 3,000 nucleotide bases apart.
Each cycle ofPCR consists ofthree steps: (1) a denaturing step, in which the target
DNA is incubated at high temperature so that the target strands are separated and
thus made accessible to the excess primers present in the reaction buffer; (2) an
annealing step, in which the reaction mixture is cooled to allow theprimers to anneal to
their complementary sequences on the target sequence; and (3) an extension reaction,
usually carried out at an intermediate temperature, in which the primers are extended
on the DNA template by a DNA polymerase. Each time a cycle iscompleted, there is a
theoretical doubling ofthe target sequence; while this doubling is probably true in the
initial cycles, in later cycles amplification becomes less efficient due to effective dilu-
tion ofthe polymerase by the large number ofavailable DNA templates. Nevertheless,
repeating this cycle many times (20- to 60-fold) results in amplification of the target
sequence over a millionfold. The amplified sequences can then be detected by gel
electrophoresis followed by blotting to nitrocellulose and probing with a 32P-labeled
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FIG. 1. The polymerase chain reaction. Each cycle of PCR consists of three steps: (1) a denaturing
step, in which the target DNA is incubated at high temperature so that the target strands are separated
("melted") and thus made accessible to the excess primers present in the reaction buffer; (2) an annealing
step, in which the reaction mixture is cooled to allow the primers to anneal to their complementary sequences
on the target sequences; and (3) an extension reaction, usually carried out at an intermediate temperature, in
which the primers are extended on the DNA template by a DNA polymerase. The extension of each strand
results in the synthesis of a primer binding site for the next round of replication; as a result of the fixed
distance between binding sites, the predominant amplification product is of discrete length-that of the
distance between the outermost ends of the primers as they are situated on the target DNA. Each time a
cycle is completed, there is a theoretical doubling of the target sequence.
probe specific for the amplified region. Alternatively, dot-blot hybridization can be
performed with no loss of sensitivity or specificity [19].
The primers are oriented in such a manner that DNA synthesis proceeds toward the
annealing site for the primer on the opposite strand; herein lies the process by which
PCR gains much of its specificity. While the probability is quite high that a given
primer will anneal nonspecifically to multiple sites in the target material, the probabil-
ity that a second primer will reproducibly (but nonspecifically) anneal to the opposite
strand at a precise position and in close proximity to the first is very low. In general, the
specifically amplified target sequence is the predominant amplification product and is
easily identified by its precisely defined length; nonspecific amplification products tend
to be heterogeneous in size, and they do not usually become the predominant product.
Two recent technical innovations have simultaneously simplified and greatly in-
creased the power of PCR. The discovery that the thermostable DNA polymerase
(Taq polymerase) [47], isolated from the thermophilic bacterium Thermus aquaticus,
is able to withstand repeated cycles of heating to 950C has made it possible to carry out
PCR without reopening tubes and adding fresh polymerase after each denaturing step.
Taq polymerase is added once at the beginning ofthe reaction, thus greatly simplifying
tube handling. Furthermore, the ability to perform annealing and extension reactions
at a higher temperature significantly reduces nonspecific amplification; the higher
temperatures are unfavorable for the formation of imperfectly base-paired complexes
between primer and target. A second innovation is the development of the program-
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mable thermal cycler. The thermal cycler, essentially a programmable heating block,
is capable of carrying out successive heating and cooling cycles unattended and
eliminates the tedious task of transferring reaction tubes between water baths or
heating blocks.
Recently a method for using mRNA as starting material for PCR has been
described 17,42]. Prior to PCR, single-stranded RNA molecules are copied into DNA
by reverse transcriptase, using oligonucleotides as primers. The resultant RNA:DNA
heteroduplexes are then amplified in the usual manner, using PCR. This technique
may have some advantages over that using a DNA substrate; the mRNA represents a
larger target because this species is often present in a several hundredfold abundance
over the DNA template. Furthermore, because eukaryotic mRNA is post-transcrip-
tionally processed by splicing out non-coding intervening sequences (introns), the
relevant coding sequence can be directly examined even though the cognate DNA
sequence is scattered across many kilobases. This approach has been taken in the
identification ofPhiladelphia chromosome (9:22) translocations, in which the chromo-
somal breakpoint may occur over 20 kilobases or more [43].
The true power of PCR is recognized when the technique is employed to amplify
rare target sequences in a background of genomic DNA. PCR has been used in the
detection of proviral sequences for human immunodeficiency virus type 1 (HIV-1)
[12-14,16]. The low prevalence in human mononuclear cells of virus-specific
sequences (as few as one copy in
1 04 to 105 cells) precludes the use of conventional
hybridization techniques. Sequences located in highly conserved regions of the HIV- 1
provirus, such as the long terminal repeat (LTR) and the gag andpol coding regions,
were targeted for amplification. The amplification products were then electrophoreti-
cally separated and blotted on to nitrocellulose. A labeled probe oligonucleotide,
corresponding to sequences flanked by the amplification oligonucleotides, was used to
confirm the presence of the specific amplification products. Using this approach, as
few as one HIV-1-infected cell could be reliably detected in a population of 106
uninfected cells [12]. Subsequent studies usingPC R to detect HIV-
1 in the peripheral
blood ofinfected individuals have confirmed the sensitivity ofthis diagnostic procedure
[16,17].
In the detection ofcytomegalovirus (CMV), PCR has been used to enhance greatly
the sensitivity of hybridization [20-22]. Whereas conventional spot hybridization
requires at least 103 TCID50 (50 percent tissue-culture infectious doses) for a positive
result [20], the polymerase chain reaction can detect from 1 to 10 TCID50 of CMV
[21,22]. Other DNA and RNA viruses have recently been detected in similar fashion;
some of these are listed in Table 2.
The Transcript Amplification System
An alternative amplification scheme, jointly developed by SISKA Diagnostics and
the Salk Institute, has recently been described [36]. This method, termed the tran-
script amplification system (TAS), can also use DNA or mRNA as starting material.
Each step of TAS consists of a cDNA synthesis step, followed by an in vitro
transcription step, using the cDNA as template. During the cDNA synthesis step, one
molecule ofDNA is produced for each DNA or RNA target by reverse trans9riptase,
and a promoter sequence for a DNA-dependent RNA polymerase is incorporated into
the newly synthesized strand. This process is made possible because the primers used in
TAS are hybrid molecules; one end of the primer consists of a target-specific region,
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TABLE 2
Application of Amplification Methods to Viral Diagnosis
Method Virus Reference
PCR Human immunodeficiency virus type 1 [12-14,16-19]
Human immunodeficiency virus type 2 [19]
Human T lymphotropic virus type I [23,24,30]
Human B lymphotropic virus [31]
Hepatitis B virus [32]
Human papillomavirus [33,34]
Cytomegalovirus [21,22]
Rhinovirus [35]
TAS Human immunodeficiency virus type 1 [36]
PCR, polymerase chain reaction
TAS, transcript amplification system
while the other end contains a promoter for the phage T7 RNA polymerase (Fig. 2).
The result is a DNA copy of the target molecule with a phage RNA polymerase
promoter at one end.
A well-established property of T7 RNA polymerase is the ability to produce many
molecules of RNA from each molecule of template, often exceeding a 30- to 40-fold
ratio ofproduct to template [48]. This feature ofT7 polymerase has been exploited in
order to provide a potent amplification step; the newly synthesized cDNA serves as
template for the synthesis by T7 polymerase of a large molar excess of RNA, which
then serves as the substrate for the next cycle. After completion of four TAS cycles,
target sequences are amplified 2-5 x 106-fold. This method has been applied to the
detection of the vifregion of the HIV-1 RNA genome, where it was determined that
fewer than one HIV-1-infected cell could bedetected in a population of 106 uninfected
cells. The amplified HIV-1-specific RNA was detected after annealing to solid-phase
bound oligonucleotides, an approach facilitated by the single-stranded structure ofthe
RNA molecules.
The use of TAS as an amplification technique may have drawbacks. Because the
enzymatic reactions of cDNA and subsequent RNA synthesis are carried out at
relatively mild temperatures (420 and 370C, respectively) nonspecific hybridization of
the oligonucleotides is more likely to occur. While TAS, like PCR, gains specificity by
requiring that two primers anneal to theirtarget sequence in relativelyclose proximity,
experience gained from early experiments with PCR has shown that increasing the
annealing temperature of the primers greatly reduces the amount of nonspecific
amplification because imperfectly base-paired complexes are less likely to occur.
Increased specificity may be possible, however, ifa second "nested" TAS primer pair,
containing a promoter for a different RNA polymerase (such as the RNA polymerase
ofeither phage SP6 or phage T3) is used after the first round ofamplification. Finally,
themultipleenzymatic steps ofTAS and the lackofthermostable reversetranscriptase
or RNA polymerase require replenishment ofenzymes at each step, resulting in more
sample handling. This last objection is somewhat tempered by the fact that only four
cycles ofamplification are required for TAS, and that, like PCR, the basic methodol-
ogy lends itselfwell to automation.
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FIG. 2. The transcript amplification system. Each step of TAS consists of synthesis of a
complementary DNA (cDNA) from an RNA templateby reverse transcription, followed by an in
vitro transcription step using the cDNA as template. During the cDNA synthesis step, one
molecule of DNA is produced for each DNA or RNA target, and a promoter sequence for a
DNA-dependent RNA polymerase is incorporated into the newly synthesized strand. This
process is made possible because the primers used in TAS are hybrid molecules; one end of the
primer consists of a target-specific region, while the other end contains a promoter for the phage
T7 RNA polymerase. The result is a DNA copy of the target molecule with a phage RNA
polymerase promoter at one end. The newly synthesized cDNA serves as template for the
synthesis by T7 polymerase ofa large molar excess ofRNA, which then serves as the substrate for
the next cycle. Four TAS cycles were sufficient to amplify the vifregion ofHIV by 2-4 x 106-fold
[36].
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POTENTIAL LIABILITIES OF TARGET AMPLIFICATION SYSTEMS
While target amplification techniques represent a new and powerful addition to
molecular diagnostics, potential liabilities may exist. One problem may stem from the
exquisite sensitivity of these techniques: namely, the issue of how many pathogens
constitutes an infection. While, in some cases, small numbers of organisms are tied to
the development of disease (such as in infection with HIV), other organisms are
ubiquitous, only causing infection when host defenses are attenuated (such as infection
with Pneumocystis carinii). The clinician must therefore weigh the results of an
extremely sensitive test with the clinical picture, knowing that tiny quantities of a
pathogen may be present in normal individuals.
Another, potentially serious problem that may arise in the use of these techniques is
the amplification of minute quantities of contaminating sequences. The nature of
amplified fragments-their short length and the invariant nature of the oligonucleo-
tide binding targets-makes them ideal substrates for further amplification. The
transfer of minuscule amounts (and in conventional detection schemes, negligible
quantities) of such sequences into a neighboring tube may result in a false positive.
When large numbers ofclinical samples are processed in a busy clinical laboratory, the
problem is compounded; the potential exists for amplified fragments to make their way
into buffers, laboratory glassware, and even the air circulation system. For this reason,
strict quality control measures must be adopted to insure that patient samples are not
contaminated.
AMPLIFICATION OF THE PROBE: THE Qf REPLICASE SYSTEM
The normal role of Qf3 replicase, an RNA-directed RNA polymerase, is to replicate
the genomic RNA of the bacteriophage Q,B [44]. The means by which this unique
polymerase carries out its task has been the subject of study for several years; it
appears that, unlike most polymerases, Qf replicase needs no oligonucleotide primer to
initiate RNA synthesis [45]. Instead, it specifically recognizes a unique folded RNA
structure, formed by intramolecular base-pairing ofthe Q,B RNA genome. Because the
replicase is highly specific for this folded structure, its properties have recently been
exploited to provide a means of amplifying hybridization signals-by amplifying the
probe molecule itself.
Lizardi and co-workers have recently described the first use of Q,B replicase to
amplify recombinant molecules containing probes specific for Plasmodium falcipa-
rum sequences that are linked to the Q13 replication site [27,29]. To do so, sequences
from the P. falciparum-specific 21 base-pair repeats [28] were inserted into the Q,B
replication origin in a DNA vector containing the phage T7 promoter. In vitro
transcription by T7 polymerase yields RNA molecules whose secondary structure is
predicted to be very similar to that of the wild-type origin, except that these molecules
harbor extensions in one loop ofthe folded structure. The recombinant RNA molecules
contained necessarily short (22 and 58 nucleotide) inserts due to the presumed size
constraints on the placement of unstructured sequences into the otherwise highly
structured replication origin. The molecules were then incubated with purified Q,B
replicase; despite the presence of the inserts, the replication of the chimeric molecules
was as efficient as that of the unmodified parent molecule, approaching 109-fold in a
single 30-minute incubation. With this degree of amplification, the replicase quickly
becomes saturated, and the reaction kinetics go from logarithmic to linear. Thus,
reactions containing more of the substrate molecules achieve saturation sooner; the
166NUCLEIC ACID AMPLIFICATION TECHNIQUES
further accumulation ofreplicated RNA is strictly time-dependent. This property may
make it possible to extend greatly the dynamic range of an assay, allowing a direct
linear relationship between the amount ofinput RNA and the amplified product.
As an approach to increasing the signal generated in a hybridization reaction, the
amplification of probe molecules has inherent disadvantages. Chief among these is
nonspecific hybridization of the probe molecule to sequences other than the intended
target; the result, in the case of the Qf replicase system, would be amplification of
nonspecific signals. If, however, the target DNA (or RNA) is first processed by nucleic
acid capture methods, such as hybridization to oligonucleotide-coated beads, back-
ground hybridization can be markedly reduced. Another means of reducing back-
ground amplification would be to design the Q,B substrates to be conformation-
dependent; only molecules specifically base-paired to their targets would be recognized
by the replicase. Advantages of the Q,B replicase system-high sensitivity, speed, and
the linear relationship between levels of target and amplified product-would,
however, seem to warrant considerable investigational effort.
AMPLIFICATION OF THE SIGNAL:
COMPOUND OR "CHRISTMAS TREE" PROBES
In the endeavor to increase a hybridization signal, one alternative to in vitro
amplification is to increase the signal generated from the probe molecule itself.
Typically, the probe molecule is a sequence of DNA or RNA, complementary to the
target sequence, that has been labeled with a "reporter group." This reporter is most
commonly a radioisotope such as 3S or 32P; detection of the signal generated by the
probe thus requires exposure to film or quantitation ofradioactive decay on a suitable
device. While radiolabeled probes generally provide the best sensitivity, their broad
acceptance has been hampered by the need to employ hazardous and expensive
radioistopes. Alternatively, the probe may comprise a small molecule that serves as
ligand for a specific antibody or a binding protein. The best studied of these non-
isotopicmethods is the biotin-avidin system, in which the probe molecule is synthesized
with biotinylated nucleotides; the incorporated biotin molecules are then targeted by
an avidin-conjugated reporter group such as horseradish peroxidase or alkaline
phosphatase, both of which produce a color reaction in the presence of a suitable
substrate [8]. While non-isotopically labeled probes have made significant inroads in
some applications, especially in in situ hybridization, their sensitivity is not high
enough for many clinical applications.
Increasing the signal generated from nucleic acid probes may be theoretically
possible ifthe reporter group can be concentrated in the probe molecule or ifthe signal
intensitygenerated byeach reporter is increased. One means ofaccomplishing this task
has recently been described by investigators at the Imclone Corporation [25]. This
system employs two types of probes simultaneously: a "primary" probe, recognizing
the target sequence and containing multiple binding sites for "secondary" probes, and
the secondary probes themselves, each of which contains a reporter group (Fig. 3).
Incubation ofthese components with target DNA sequences results in the formation of
a "Christmas tree" probe network, in which the primary probe is bound to its target via
its target-specific region, leaving the unbound sequence available for binding by the
reporter-bearing secondary probes. The probe trees thus generated can assume a
variety of shapes, depending on whether the primary and secondary probes are linear
or circular, but the net result is the same; the signal-generating capability ofthe probe
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FIG. 3. Compound or "Christmas tree" probes. Compound probe systems employ twotypesofprobes
simultaneously: a "primary" probe, recognizing thetargetsequenceandcontaining multiplebindingsites for
"secondary" probes, and the secondary probes themselves, each of which contains a reporter group.
Incubation of these components with target DNA sequences results in the formation of a probe network
("Christmas tree"), in which the primary probe is bound to its target via its target-specific region, leaving
the unbound sequence available for binding by the reporter-bearing secondary probes.
is significantly increased. The outcome, in practical terms, is the ability to detect
smaller amounts ofa target sequence or to ascertain the presence ofa given amount of
the target in a shorter period oftime.
This approach lends itselfwell to the use ofnon-isotopic reporter groups such as calf
intestine alkaline phosphatase or horseradish peroxidase. These enzymes are com-
monly used in immunodiagnostics because they areable tocatalyze theproduction ofa
relatively large amount of analyzable product, thus increasing sensitivity. Secondary
probes, consisting ofoligonucleotides coupled to these enzymes, could be used in place
oftheir radioactively labeled counterparts. Ifhigh-stringency conditions for hybridiza-
tion are required, however, enzymatic activity may be lost due to the higher incubation
temperatures required. Alternative non-isotopic detection schemes include the use of
fluorescent orchemiluminescent secondary probes. Thelower signal-generating capac-
ity of probes ofthis type is offset by their thermal stability; the use ofthe "Christmas
tree" approach may boost thesignal produced topractical levels. Fluorescently labeled
oligonucleotides have recently been employed as secondary probes in a compound
probe system developed by the Chiron Corporation for the detection of Neisseria
gonorrhoeae and Chlamydia trachomatis [26].
CONCLUSIONS
The promise of the technical innovations described here is to increase greatly the
sensitivity and speed of nucleic acid hybridization techniques. Although the full
ramifications of these developments are difficult to foresee, several predictions can be
made regarding their place in the clinical microbiology laboratory ofthe future. First,
these techniques will provide new tools for the identification of pathogens whose
identification has previously been limited by the lack of a practical culture system.
While an exhaustive list ofall such organisms is beyond the scope ofthis review, Table
2 includes a compilation of viruses that have so far been successfully identified by in
vitro amplification techniques. (Not surprisingly, the list is dominated by viral
pathogens whose detection by these means represents an improvement over existing
techniques.) Second, the high sensitivity of these approaches may alter patient
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sampling requirements. Forexample, buccal epithelial cells derived from a mouthwash
have been successfully used to identify carrier status for the cystic fibrosis allele [6].
One can envision the use of urinary sediments in the place of urethral swabs in the
diagnosis of urethritis, peripheral blood instead of bone marrow or liver biopsy in the
diagnosis of atypical myobacterial infections, and peripheral blood mononuclear cells
instead ofbone marrow biopsy in thedetection ofrecurrent leukemiasand lymphomas.
Third, the emergence of amplification techniques will decrease reliance on radiola-
beled probes; the sensitivity previously attainable only with such probes will probably
be achieved by combining amplification methods with non-radioactive reporter sys-
tems. Finally, if the potential problems of sample cross-contamination can be ad-
dressed and overcome, amplification methods may form the basis ofa fully automated
nucleic acid detection system.
The clinical implications of rapid and sensitive assays for viral diagnosis are many
[15]. Amplification techniques have already demonstrated their utility in the detection
of viral pathogens whose in vitro cultivation has been difficult (HIV-1, HIV-2,
HTLV-1, human B lymphotropic virus), lengthy (CMV), or unavailable (human
papillomavirus, hepatitis B virus) (Table 2). Although these techniques have already
proven their power in the research setting, the development of sensitive, stable,
non-radioactive probes and the simplification ofmethods will both be required before
this technology can make the transition to the clinical laboratory. Significant progress
in the development of in vitro amplification techniques has been achieved within a
relatively short period; the application ofthese new methodologies to both new and old
clinical problems holds great promise for the future.
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